fulcrum

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

3 weeks ago

September 12, 2025 16:30 ET | Source: Fulcrum Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics,…

3 months ago